Slide 1: Fourth Quarter and Full Year Earnings Presentation
AngioDynamics Fourth Quarter and Full Year Earnings Presentation July 15, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: FY Q4 2025 Key Takeaways
FY Q4 2025 Key Takeaways Continued commercial and operational execution positions AngioDynamics to drive accelerated, profitable growth moving forward Continued Commercial Execution – Fiscal Q4 FY 2025 Total Med Tech Med Device Segment YoY Revenue Growth +12.7% +22.0% +6.2% pro forma pro forma pro f
Slide 4: Q4 FY 2025 Financial Snapshot
Q4 FY 2025 Financial Snapshot Net Sales Segment Revenue Contribution $80.2 Q4 24 Q4 25 $71.1 $35.8 +22.0% 59% 55% Pro Forma Growth 41% 45% $29.3 Med Tech Med Device Med Tech Med Device +6.2% Segment Gross Margin* $41.8 $44.4 Pro Forma Growth *Inclusive of tariffs 47.6% 59.0% Q4 24 Q4 25 Med Device M
Slide 5: FY 2025 Financial Snapshot
FY 2025 Financial Snapshot Net Sales Segment Revenue Contribution $292.7 $270.7 FY 24 FY 25 $126.7 $106.0 +19.5% 61% 57% Pro Forma Growth 39% 43% Med Tech Med Device Med Tech Med Device $166.0 +0.8% Segment Gross Margin* $164.8 *Inclusive of tariffs Pro Forma Growth 47.7% 62.0% FY 24 FY 25 Med Devic
Slide 6: Med Tech - Auryon
Med Tech - Auryon Period Sales YoY Growth Q4 2025 $15.6M +19.7% FY 2025 $56.9M +20.8% • Cumulative sales of ~$185M since launch in Sept 2020, with over 130,000 procedures performed globally • Continued penetration into hospital setting • Seeing positive impacts of recently launched catheters (1.7mm
Slide 7: Med Tech - Thrombus Management
Med Tech - Thrombus Management 4Q 2025 Sales YoY Growth FY 2025 Sales YoY Growth AngioVac $8.2M 39.5% AngioVac $28.9M 25.1% AlphaVac $3.1M 60.8% AlphaVac $10.8M 59.5% Total Mech Thromb. $11.3M 44.7% Total Mech Thromb. $39.7M 32.9% Unifuse $1.7M 51.5% Unifuse $5.6M 23.2% Total Thrombus Mgmt. $13.0M 4
Slide 8: Med Tech - NanoKnife
Med Tech - NanoKnife 4Q 2025 Sales YoY Growth FY 2025 Sales YoY Growth Disposables $5.7M +5.5% Disposables $19.7M +9.6% Capital $1.5M -24.9% Capital $4.8M -26.0% Total $7.2M -2.5% Total $24.5M +0.1% • Received Prostate Tissue CPT Category 1 Code (effective Jan. 1, 2026), which is expected to streaml
Slide 9: Med Device
Med Device 4Q 2025 Sales YoY Growth FY 2025 Sales YoY Growth Core Peripheral $21.5M +8.5% Core Peripheral $78.3M +2.6% Venous / EVLT $7.3M +14.3% Venous / EVLT $27.5M +3.3% Ports $9.1M -3.5% Ports $36.0M -0.7% Solero Microwave $4.9M +5.8% Solero Microwave $18.4M -4.1% Alatus and Isoloc Balloons $1.0
Slide 10: Fiscal Year 2026 Guidance
Fiscal Year 2026 Guidance Metric Guidance* Tariff Guidance Impact* (Issued Jul. 15, 2025) Full Year Net Sales $305M - $310M Limited Impact Med Tech Net Sales 12 – 15% YoY growth Limited Impact Med Device Net Sales Flat Limited Impact Gross Margin 53.5% - 55.5% Absent Tariffs: 55.0% - 56.0% Pro Forma
Slide 11: Appendix
Appendix 11
Slide 12: Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements (in thousand, except per share data) 12
Slide 13: Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and EPS
Reconciliation of GAAP Net Loss to Non- Reconciliation of Net Loss to Adjusted GAAP Adjusted Net Loss and EPS EBITDA (in thousands, except per share data) (in thousands, except per share data) 13
Slide 14: Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss and EPS
Reconciliation of Non-GAAP Pro Forma Net Reconciliation of Non-GAAP Pro Forma Loss to Adjusted Pro Forma Net Loss and EPS Net Loss to Adjusted Pro Forma EBITDA (in thousands, except per share data) (in thousands, except per share data) 14
Slide 15: Detail of Acquisition, Restructuring and Other Items, net
Detail of “Acquisition, Restructuring and Other Items, net” 15
Slide 16: Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category
Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category (in thousands) 16
Slide 17: Reconciliation of Free Cash Flows
Reconciliation of Free Cash Flows (in thousands) 17